TwinBeech Capital’s Acceleron Pharma XLRN Stock Holding History

TwinBeech Capital’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-9,123	Closed	-$1.15M	–	829
2021 Q2	$1.15M	Buy	+9,123	New	+$1.15M	0.14%	201

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

TwinBeech Capital's XLRN Position: Q3 2021 in Review

TwinBeech Capital sold out of Acceleron Pharma (XLRN) in Q3 2021, closing a stake of 9,123 shares — an estimated $1.15M sold.

TwinBeech Capital first reported a position in XLRN in Q2 2021 and held it in 1 quarter. The position peaked at $1.15M in Q2 2021. 330 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

TwinBeech Capital reported no remaining Acceleron Pharma position as of Q3 2021 after selling out during the quarter.
TwinBeech Capital sold 9,123 Acceleron Pharma shares in Q3 2021, an estimated $1.15M.
TwinBeech Capital first reported a position in Acceleron Pharma in Q2 2021 and held it in 1 quarter.
TwinBeech Capital's Acceleron Pharma position peaked at $1.15M in Q2 2021.
330 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on TwinBeech Capital's 13F filing for Q3 2021, filed 15 Nov 2021.